Continuous Glucose Monitoring in Kidney Transplant Recipients with Diabetes, Pre-diabetes and Without Diabetes

What this Trial Is About

This research aims to study glucose levels measured by continuous glucose monitoring (CGM) immediately after kidney transplantation in patients with diabetes, prediabetes, and no diabetes. The primary goal is to compare the average glucose levels among these three groups. This study also explores other glucose-related measures, adherence to guidelines, changes in HbA1c, and the effects of immunosuppressive and steroid treatments on beta cell function. Participants will be grouped into diabetes, prediabetes, and no diabetes categories, with 18 people in each group. CGM devices will be applied within 72 hours after kidney transplantation and will monitor glucose levels continuously for 10 to 14 days. Blood samples for HbA1c, C-peptide, and insulin will be collected at the start and end of CGM monitoring. Medical records will be reviewed for medications, complications, and vital signs during CGM use. Physicians will manage glucose levels according to standard guidelines without access to CGM data. During the study, participants will have a CGM sensor measuring glucose multiple times daily for up to two weeks post-transplant. Researchers will assess glucose patterns, including time spent in target glucose ranges and episodes of high or low blood sugar. Outcomes include mean sensor glucose over 10 days and other glucose variability measures. Data will be analyzed to understand glucose differences between groups and factors influencing glucose control. The total participation time involves CGM wear and blood sample collection within the first two weeks after transplantation.

Continuous Glucose Monitoring (CGM) After Kidney Transplantation